Paolo Tarantino, Datopotamab Deruxtecan
Paolo Tarantino/X

Paolo Tarantino: Datopotamab Deruxtecan Improves Outcomes in IO-Ineligible mTNBC

Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn:

“No better news to start the week: in TROPION-Breast02, first-line datopotamab deruxtecan improved PFS and OS over chemo for IO-ineligible patients with metastatic TNBC.

ADCs keep delivering, are rapidly climbing to earlier lines of treatment across breast cancer subtypes.

Hope to see the full results at ESMO25.”

Paolo Tarantino: Datopotamab Deruxtecan Improves Outcomes in IO-Ineligible mTNBC

Read further.

More posts featuring Paolo Tarantino.